Pilot study of a pediatric metronomic 4-drug regimen

Oncotarget

Volumn 2, Issue 12, 2011, Pages 960-965

  André, Nicolas ^a,b   Abed, Sylvie ^a   Orbach, Daniel ^c   Alla, Corinne Armari ^d   Padovani, Laetitia ^a   Pasquier, Eddy ^b,e   Gentet, Jean Claude ^a   Verschuur, Arnauld ^a,b  

^a TIMONE HOSPITAL   (France)

^b Metronomics Global Health Initiative   (France)

^c INSTITUT CURIE   (France)

^d Service d'Oncologie Pédiatrique   (France)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Angiogenesis; Immune system; Metronomic chemotherapy; Pediatric oncology

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOPHOSPHAMIDE; METHOTREXATE; PYRAZOLE DERIVATIVE; SULFONAMIDE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; NEOPLASM; PILOT STUDY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, METRONOMIC; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; NEOPLASMS; PILOT PROJECTS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 84861234300     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.358     Document Type: Article

References (26)

1. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nature Rev Clin Oncol. 2010; 7: 455-65.
2. Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, Kivivuori MS, Peyrl A, Diawarra M, Casanova M, Zacharoulis S, Vassal G, Berthold F, Verschuur A, André N. Moving forward with metronomic treatments: meeting report of the 2nd international workshop on metronomic and anti-angiogenic chemotherapy in paediatric oncology. Transl Oncol. 2011; 4: 189-97.
3. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005; 27: 573-81.
4. Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, BajciovaV, Zitterbart K, Kadlecova V, Mazanek P. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. 2006; 29: 308-13.
5. Choi JMR, Kamani N, La Fond D, Packer RJ, Santi MR, Macdonald TJ. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer. 2008; 50: 970-5.
6. Traore F, Diawara M, Pasquier E, André N. Children Treated With Metronomic Chemotherapy in a Low-income Country: METRO-MALI-01. Pediatr Hematol Oncol. 2011; 33: 31-4.
7. Klement GL, Kamen BA. Nontoxic, Fiscally Responsible, Future of Oncology: Could it be Beginning in the Third World? J Pediatr Hematol Oncol. 2011; 33:1-3.
8. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4: 23-36.
9. André N, Pasquier E. Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'. Nat Clin Pract Oncol. 2009; 6(2):E1.
10. André N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC. Metronomical Etoposide/Cyclophosphamide/Celocoxib regimen given to children with refractory cancer: a preliminary monocentric study. Clin Pharm. 2008; 30: 1336-40.
11. Le Deley MC, Vassal G, Taïbi A, Shamsaldin A, Leblanc T, Hartmann O. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer. 2005; 45: 25-31.
12. Dufour C, Da Costa L, Auger N, Jullien M, Bhangoo R, Grill J. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. J Pediatr Hematol Oncol. 2008; 30: 857-9.
13. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002; 13: 73-80.
14. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006; 28: 720-8.
15. Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007; 25: 501-6.
16. Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007; 7: 566-81.
17. Mabeta P, Pepper MS. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Apoptosis. 2009; 12: 81-90.
18. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009; 69: 6987-94.
19. Ponthan F, Wickström M, Gleissman H, Fuskevåg OM, Segerström L, Sveinbjörnsson B, Redfern CP, Eksborg S, Kogner P, Johnsen JI. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res. 2007; 13: 1036-44.
20. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials. 2000; 21:343-59.
21. Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever happened to N-of-1 trials? Insiders' perspectives and a look to the future. Milbank Q. 2008; 86: 533-55.
22. Sterba J, Pavelka Z, André N, Ventruba J, Skotakova J, Bajciova V, Bronisova D, Dubska L, Valik D. Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatr Blood Cancer. 2010; 54: 616-17.
23. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1999; 26: 2539-43.
24. Minturn JE, Janss AJ, Fisher PG, Allen JC, Patti R, Phillips PC, Belasco JB. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer. 2011; 56: 39-44.
25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009; 45: 228-47.
26. Kivivuori SM, Riikonen P, Valanne L, Lönnqvist T, Saarinen-Pihkala UM. Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas. Acta Paediatr. 2011; 100: 134-38.